{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=87&status=ACTIVE_NOT_RECRUITING", "query": { "status": "ACTIVE_NOT_RECRUITING", "page": 87 }, "page_size": 10 }, "pagination": { "page": 87, "page_size": 10, "total_count": 10535, "total_pages": 1054, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=88&status=ACTIVE_NOT_RECRUITING&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=86&status=ACTIVE_NOT_RECRUITING&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T03:57:18.481Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05003843", "title": "BOLT-DVT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Deep Vein Thrombosis", "DVT" ], "interventions": [ { "name": "Indigo Aspiration System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Penumbra Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2021-09-30", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-11-15T03:57:18.481Z", "location_count": 42, "location_summary": "La Mesa, California • Long Beach, California • Los Angeles, California + 32 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05003843" }, { "nct_id": "NCT05741125", "title": "Improving Appetite Self-Regulation in African American Adults With Type 2 Diabetes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 2 Diabetes", "Binge Eating" ], "interventions": [ { "name": "DSME + ASE intervention (Centering Appetite)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2025-01-22", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-11-15T03:57:18.481Z", "location_count": 2, "location_summary": "Kannapolis, North Carolina", "locations": [ { "city": "Kannapolis", "state": "North Carolina" }, { "city": "Kannapolis", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05741125" }, { "nct_id": "NCT05898776", "title": "10°C vs 4°C Lung Preservation RCT", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Transplant", "Organ Preservation" ], "interventions": [ { "name": "Lung transplantation after 10°C donor lung preservation", "type": "DEVICE" }, { "name": "Lung transplantation after standard ice cooler donor lung preservation", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University Health Network, Toronto", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 317, "start_date": "2023-06-09", "completion_date": "2026-11-22", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-11-15T03:57:18.481Z", "location_count": 7, "location_summary": "Phoenix, Arizona • San Francisco, California • Coral Gables, Florida + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05898776" }, { "nct_id": "NCT02511106", "title": "AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage IB-IIIA Non-small Cell Lung Carcinoma" ], "interventions": [ { "name": "AZD9291 80 mg/40 mg", "type": "DRUG" }, { "name": "Placebo AZD9291 80 mg/40 mg", "type": "DRUG" }, { "name": "Open-label AZD9291 80 mg/40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 682, "start_date": "2015-10-21", "completion_date": "2029-01-31", "has_results": true, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-11-15T03:57:18.481Z", "location_count": 23, "location_summary": "Los Angeles, California • Santa Monica, California • Santa Rosa, California + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Grand Junction", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02511106" }, { "nct_id": "NCT04663347", "title": "Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone", "type": "DRUG" }, { "name": "Rituximab and Lenalidomide", "type": "DRUG" }, { "name": "rituximab and bendamustine", "type": "DRUG" }, { "name": "rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin", "type": "DRUG" }, { "name": "gemcitabine and oxaliplatin", "type": "DRUG" }, { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "rituximab, ifosfamide, carboplatin, and etoposide phosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 543, "start_date": "2020-11-03", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-15T03:57:18.481Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04663347" }, { "nct_id": "NCT06268015", "title": "Botensilimab and Balstilimab Optimization in Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Botensilimab", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nicholas DeVito, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2024-11-18", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-11-15T03:57:18.481Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06268015" }, { "nct_id": "NCT07526935", "title": "Combined Role of Gastric Peroral Endoscopic Myotomy and Gastric Electrical Stimulator", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gastroparesis" ], "interventions": [ { "name": "GES + Upper endoscopy", "type": "DEVICE" }, { "name": "GES on + Upper endscopy", "type": "DEVICE" }, { "name": "GES off + G-POEM", "type": "PROCEDURE" }, { "name": "GES on + G-POEM", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-03-19", "completion_date": "2028-12-30", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-11-15T03:57:18.481Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07526935" }, { "nct_id": "NCT02632708", "title": "Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Newly Diagnosed Acute Myeloid Leukemia (AML)", "Untreated AML", "AML Arising From Myelodysplastic Syndrome (MDS)", "AML Arising From Antecedent Hematologic Disorder (AHD)", "AML Arising After Exposure to Genotoxic Injury" ], "interventions": [ { "name": "AG-120", "type": "DRUG" }, { "name": "AG-221", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "mitoxantrone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2015-12-31", "completion_date": "2026-07-24", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-11-15T03:57:18.481Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632708" }, { "nct_id": "NCT06864208", "title": "Addressing Weight Bias Internalization to Improve Adolescent Weight Management Outcomes: Randomized Pilot Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Weight", "Body Weight", "Weight Bias", "Weight Stigma", "Physiological Stress", "Biological Markers of Stress", "Biological Markers of Inflammation", "Eating Behaviors" ], "interventions": [ { "name": "Behavioral Weight Management", "type": "BEHAVIORAL" }, { "name": "Weight Bias Internalization", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "The Miriam Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "13 Years to 17 Years" }, "enrollment_count": 64, "start_date": "2025-03-25", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-11-15T03:57:18.481Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT06864208" }, { "nct_id": "NCT06400225", "title": "Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Ulixertinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2019-07-24", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-15T03:57:18.481Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06400225" } ] }